These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28838717)

  • 41. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
    Waqar SN; Morgensztern D
    Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibiotics and proton pump inhibitors suppress the efficacy of immunotherapy against non-small cell lung cancer.
    Diao X
    Thorac Cancer; 2020 Jul; 11(7):1763-1764. PubMed ID: 32374445
    [No Abstract]   [Full Text] [Related]  

  • 43. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.
    Klein O; Kee D; Markman B; Carlino MS; Underhill C; Palmer J; Power D; Cebon J; Behren A
    Cancer Cell; 2021 May; 39(5):592-593. PubMed ID: 33930312
    [No Abstract]   [Full Text] [Related]  

  • 45. Stereotactic Ablative Radiotherapy Induces Peripheral T-Cell Activation in Patients with Early-Stage Lung Cancer.
    de Goeje PL; Smit EF; Waasdorp C; Schram MTB; Kaijen-Lambers MEH; Bezemer K; de Mol M; Hartemink KJ; Nuyttens JJME; Maat APWM; Hegmans JPJJ; Hendriks RW; Senan S; Aerts JGJV
    Am J Respir Crit Care Med; 2017 Nov; 196(9):1224-1227. PubMed ID: 28345951
    [No Abstract]   [Full Text] [Related]  

  • 46. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunotherapy for non-small-cell lung cancer.
    Thomas A; Jakopovic M
    Expert Opin Biol Ther; 2014 Aug; 14(8):1061-4. PubMed ID: 24878420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel antigens in non-small cell lung cancer: SP17, AKAP4, and PTTG1 are potential immunotherapeutic targets.
    Mirandola L; Figueroa JA; Phan TT; Grizzi F; Kim M; Rahman RL; Jenkins MR; Cobos E; Jumper C; Alalawi R; Chiriva-Internati M
    Oncotarget; 2015 Feb; 6(5):2812-26. PubMed ID: 25739119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Immuno-Oncology therapeutic principles in lung and renal cell carcinoma].
    Wolf J; Grünwald V
    Oncol Res Treat; 2014; 37 Suppl 4():10-3. PubMed ID: 25301191
    [No Abstract]   [Full Text] [Related]  

  • 51. Evolving Treatment Options for Lung Cancer.
    Morgensztern D; Herbst RS
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):xiii-xiv. PubMed ID: 27912837
    [No Abstract]   [Full Text] [Related]  

  • 52. A New Immunotherapy Drug Creates a Watershed for the Surgical Pathologist's Role in Patient Care.
    Cagle PT; Bernicker EH
    Arch Pathol Lab Med; 2015 Nov; 139(11):1329. PubMed ID: 26516934
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.
    Steendam CM; Dammeijer F; Aerts JGJV; Cornelissen R
    Immunotherapy; 2017 May; 9(6):507-520. PubMed ID: 28472903
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
    Hall RD; Gray JE; Chiappori AA
    Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer vaccines: a new therapeutic alternative for lung cancer therapy?
    Raez LE; Santos ES
    Immunotherapy; 2009 Sep; 1(5):727-8. PubMed ID: 20636014
    [No Abstract]   [Full Text] [Related]  

  • 56. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeted Therapy and Immunotherapy for Lung Cancer.
    Naylor EC; Desani JK; Chung PK
    Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Fabre E; Pécuchet N; Cadranel J
    Bull Cancer; 2016 Nov; 103 Suppl 1():S138-S143. PubMed ID: 28057177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is vaccine therapy a renewed strategic approach for non-small-cell lung cancer therapy?
    Rossi A
    Expert Rev Vaccines; 2013 Jan; 12(1):5-7. PubMed ID: 23256734
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.